Division of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Cardiology Unit, Azienda Ospedaliera "Card G. Panico", Tricase, Italy.
Acta Cardiol. 2024 May;79(3):367-373. doi: 10.1080/00015385.2024.2310930. Epub 2024 Mar 5.
Conduction system disorders represent a frequent complication in patients undergoing surgical (surgical aortic valve replacement, SAVR) or percutaneous (transcatheter aortic valve implantation, TAVI) aortic valve replacement. The purpose of this survey was to evaluate experienced operators approach in this clinical condition.
This survey was independently conducted by the Italian Association of Arrhythmology and Cardiac Pacing (AIAC) and it consisted of 24 questions regarding the respondents' profile, the characteristics of participating centres, and conduction disease management in different scenarios.
Fifty-five physicians from 55 Italian arrhythmia centres took part in the survey. Prophylactic pacemaker implantation is rare. In case of persistent complete atrioventricular block (AVB), 49% and 73% respondents wait less than one week before implanting a definitive pacemaker after SAVR and TAVI, respectively. In case of second degree AVB, the respondents wait some days more for definitive implantation. Respondents consider bundle branch blocks, in particular pre-existing left bundle branch block (LBBB), the worst prognostic factors for pacemaker implantation after TAVI. The implanted valve type is considered a relevant element to evaluate. In patients with new-onset LBBB and severe/moderate left ventricular systolic dysfunction, respondents would implant a biventricular pacemaker in 100/55% of cases, respectively.
Waiting time before a definitive pacemaker implantation after aortic valve replacement has reduced compared to the past, and it is anticipated in TAVI vs. SAVR. Bundle branch blocks are considered the worse prognostic factor for pacemaker implantation after TAVI. The type of pacemaker implanted in new-onset LBBB patients without severe left ventricular systolic dysfunction is heterogeneous.
在接受外科(主动脉瓣置换术,SAVR)或经皮(经导管主动脉瓣植入术,TAVI)主动脉瓣置换术的患者中,传导系统疾病是一种常见并发症。本研究旨在评估有经验的术者在这种临床情况下的处理方法。
该研究由意大利心律失常和心脏起搏协会(AIAC)独立进行,共包含 24 个问题,涉及受访者的个人资料、参与中心的特点以及不同情况下的传导疾病管理。
来自意大利 55 个心律失常中心的 55 名医生参与了本项调查。预防性起搏器植入较为少见。在持续性完全性房室传导阻滞(AVB)的情况下,分别有 49%和 73%的受访者在 SAVR 和 TAVI 后等待不到一周的时间来植入永久性起搏器。对于二度房室传导阻滞,受访者会多等待几天再进行永久性起搏器植入。受访者认为束支传导阻滞,特别是先前存在的左束支传导阻滞(LBBB),是 TAVI 后起搏器植入的最不利预后因素。植入的瓣膜类型被认为是一个重要的评估因素。在新发 LBBB 且左心室射血分数严重/中度降低的患者中,分别有 100%和 55%的受访者会植入双心室起搏器。
与过去相比,主动脉瓣置换术后永久性起搏器植入的等待时间已经缩短,在 TAVI 中较 SAVR 更为明显。束支传导阻滞被认为是 TAVI 后起搏器植入的最不利预后因素。在新发 LBBB 且无严重左心室收缩功能障碍的患者中,植入的起搏器类型存在差异。